Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

Get the latest Eisai Co., Ltd. (ESAIY) stock news and headlines to help you in your trading and investing decisions.